Education
About Us
Working with TipRanks
Follow Us
Genmab A/S (GMAB)
NASDAQ:GMAB
Total Valuation
Genmab has a market cap or net worth of $13.57B. The enterprise value is $88.88B.
Market Cap$13.57B
Enterprise Value$88.88B
Share Statistics
Genmab has 641,221,400 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding641,221,400
Owned by Insiders―
Owned by Institutions2.51%
Financial Efficiency
Genmab’s return on equity (ROE) is 0.21 and return on invested capital (ROIC) is 14.13%.
Return on Equity (ROE)0.21
Return on Assets (ROA)0.17
Return on Invested Capital (ROIC)14.13%
Return on Capital Employed (ROCE)0.17
Revenue Per Employee8.16M
Profits Per Employee2.97M
Employee Count2,638
Asset Turnover0.47
Inventory Turnover15.89
Valuation Ratios
The current PE Ratio of Genmab is 12.39. Genmab’s PEG ratio is -0.97.
PE Ratio12.39
PS Ratio0.00
PB Ratio17.48
Price to Fair Value2.65
Price to FCF14.24
Price to Operating Cash Flow14.14
PEG Ratio-0.97
Income Statement
In the last 12 months, Genmab had revenue of 21.53B and earned 7.84B in profits. Earnings per share was 12.14.
Revenue21.53B
Gross Profit20.54B
Operating Income6.70B
Pretax Income9.16B
Net Income7.84B
EBITDA7.39B
Earnings Per Share (EPS)12.14
Cash Flow
In the last 12 months, operating cash flow was 6.54B and capital expenditures -199.00M, giving a free cash flow of 6.35B billion.
Operating Cash Flow6.54B
Free Cash Flow6.35B
Free Cash Flow per Share9.90
Dividends & Yields
Genmab pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.60
52-Week Price Change-16.40%
50-Day Moving Average20.25
200-Day Moving Average21.86
Relative Strength Index (RSI)68.87
Average Volume (3m)1.37M
Important Dates
Genmab upcoming earnings date is Aug 7, 2025, TBA Not Confirmed.
Last Earnings DateMay 8, 2025
Next Earnings DateAug 7, 2025
Ex-Dividend Date―
Financial Position
Genmab as a current ratio of 5.25, with Debt / Equity ratio of 2.70%
Current Ratio5.25
Quick Ratio5.24
Debt to Market Cap0.00
Net Debt to EBITDA-1.19
Interest Coverage Ratio55.86
Taxes
In the past 12 months, Genmab has paid 1.32B in taxes.
Income Tax1.32B
Effective Tax Rate0.14
Enterprise Valuation
Genmab EV to EBITDA ratio is 0.12, with an EV/FCF ratio of 0.12.
EV to Sales0.04
EV to EBITDA0.12
EV to Free Cash Flow0.12
EV to Operating Cash Flow0.11
Balance Sheet
Genmab has $3.23B in cash and marketable securities with kr143.00M in debt, giving a net cash position of -$3.08B billion.
Cash & Marketable Securities$3.23B
Total Debtkr143.00M
Net Cash-$3.08B
Net Cash Per Share-$4.81
Tangible Book Value Per Share$337.58
Margins
Gross margin is 95.35%, with operating margin of 31.14%, and net profit margin of 36.44%.
Gross Margin95.35%
Operating Margin31.14%
Pretax Margin42.57%
Net Profit Margin36.44%
EBITDA Margin34.33%
EBIT Margin32.89%
Analyst Forecast
The average price target for Genmab is $30.67, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$30.67
Price Target Upside34.28% Upside
Analyst ConsensusModerate Buy
Analyst Count6
Revenue Growth Forecast25.11%
EPS Growth Forecast46.46%